Welcome to the Wet AMD & DME Drug Development Summit

The second edition of the industry-led Wet AMD & DME Drug Development Summit arrives in Boston to give you comprehensive insight into the current and emerging angiogenesis- inflammatory-directed and anti-fibrotic drug development programs for these three ophthalmic conditions – neovascular age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and diabetic macular edema (DME).

Join this dedicated industry forum to network online and learn from senior leaders of discovery, translational sciences, and clinical development from the likes of Roche, Genentech, Novartis, Apellis, Outlook Therapeutics and more, to address the specific challenges for the biopharmaceutical and biotechnology in its efforts to bring long-lasting treatments which reduce clinical burden and can be commercialized to become the new standard-of-care in this vast ophthalmology indication.

Navigate across 3 jam-packed days including two interactive workshops exploring the optimization of administration techniques and viral and non-viral vectors to deliver safe & durable anti-angiogenic therapies to the eye and developing preclinical and translational models to predict human disease and efficacy of a drug.

Expert Speakers Include:

Eliot Lazar

President, Medical Doctor

eLCON Medical

Maria Gemenetzi

Global Drug Development and clinical analysis CD&A

Novartis Pharmaceuticals UK Ltd

Mina Sooch

Chief Executive Officer

Ocuphire

Peter Kaiser

Professor of Opthalmology

Cleveland Clinic

David Lally

Vitreoretinal Surgeon & Clinical Investigator

New England Retina Associates

Marion Munk

Chief Medical Officer

Isarna THerapeutics

Stephen Poor

Director External Innovation and Translational Biomarkers

Novartis Institutes for Biomedical Research, Department of Ophthalmology

Zhichao Wu

Principal Investigator

Centre for Eye Research Australia

2022 Sponsoring Partners:

Who Attended in 2021?

abbvie
Aerie-Pharmaceuticals-Logo
Alkahest-logo
Allgenesis Bio
boehringer
Catalyst
Gemini Therapeutics
Genentech-Logo.wine
Graybug
gyroscope-vision-for-life-logo-dark-new
iconic
daichii
kala-logo-footer
meduniwienlogo_2-1746
novartis
ocular
Yale-University-Logo-Header-VNIOiena8OGMXs8hu65vBXbujKPXBcgD
radboud-university
regeneron
IU_V_P1_S1
Roche_Logo.svg
Santen_Pharmaceutical_company_logo.svg
Spark_Therapeutics_Label
surrozen-logo-final-large-1
polyactiva
wake forest

Feedback from the Wet AMD & DME Drug Development Summit:

“Outstanding program with diverse and salient presentations regarding advances in the treatment of Wet AMD and DME”

CEO, ForwardVue Pharma

“Comprehensive and informative”

Chief Medical Officer, Chair-Cell Biology of the Faculty of Science, Radboud University Nijmegen